Understanding genetic changes in neuroblastoma cells to pave the way for targeted treatments
Investigation of the effects of DNA repair inhibitors in pre-clinical models of neuroblastomas with ATM, MYCN and TP53 abnormalities
Understanding what goes wrong in cells that leads to malignant rhabdoid tumours
Unravelling the impact of SMARCB1 loss on the chromatin landscape in malignant rhabdoid tumor to identify novel therapeutic opportunities
Investigating a newly discovered gene to improve our understanding of Wilms tumour
Epigenetic deregulation of splicing in childhood renal malignancies
Improving our understanding of leukaemia that has spread throughout the body
Defining the tumour microenvironment in extramedullary acute leukaemia
Discovering the differences between craniopharyngiomas that regrow after treatment and those that don't
Molecular profiling of relapsing craniopharyngioma
Helping to develop research into antibody treatment
Investigation of ganglioside-specific receptor expression by tumour-infiltrating immune cells
Improving our understanding of how chemotherapy works in hepatoblastoma
Analysis of genome-wide 5-hydroxymethylcytosine patterns in human hepatoblastoma tumours during chemotherapy treatment
Repurposing mebendazole and albendazole for acute myeloid leukaemia
Testing the use of mebendazole and albendazole for children with acute myeloid leukaemia, and investigating how the drugs work.
Improving treatment and reducing side effects for children with B-cell NHL
Identification of new drug targets to improve treatment options and reduce treatment-related toxicity for children diagnosed with aggressive B-cell non-Hodgkin lymphoma (B-NHL)